Endo was outbid in developing treatment for gastrointestinal diseases because, rival, Canadian pharmaceutical Valeant increased its offer for Salix.

"By offering a significant premium with a 100 percent cash offer, eliminating market and company equity risk that could arise from other non-cash offers with a four month closing timeline instead of a closing by April 1st, our new arrangement creates significant shareholder value for Salix," Valeant chief executive Michael Pearson said.
The Laval, Quebec-based company's takeover of Salix will mark its first major transaction since it came up short in a hostile tender for Botox maker Allergan last year.
Allergan was eventually taken over by Actavis.
Endo, meanwhile, said in a statement that it was "disappointed with this outcome," but would move forward with its other growth plans.
The Valeant-Salix deal, which Valeant forecast would boost its revenues by 20 percent next year, is expected to close April 1.
Advertisement
Source-Medindia/